β-adrenergic receptor blockers and weight gain a systematic analysis

Hypertension

Volumn 37, Issue 2 I, 2001, Pages 250-254

  Sharma, Arya M ^a,b   Pischon, Tobias ^a   Hardt, Sandra ^a   Kunz, Iris ^a   Luft, Friedrich C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Body weight; Hypertension, obesity; Obesity; blockers

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CILAZAPRIL; DOXAZOSIN; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; METOPROLOL; PROPRANOLOL; SPIRONOLACTONE;

BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID STORAGE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REVIEW; BODY WEIGHT; DRUG EFFECT; PATHOPHYSIOLOGY; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; BODY WEIGHT; HUMANS; HYPERTENSION; WEIGHT GAIN;

EID: 0035090283     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.37.2.250     Document Type: Review

References (49)

1. The sixth report of the joint national committee on prevention. Detection. Evaluation and treatment of high blood pressure
2. Sympathetic overactivity in hypertension: A moving target
3. Beta-blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication myth
4. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
5. Metabolic considerations in the choice of therapy for the patient with hypertension
6. Effects of antihypertensive therapy on insulin resistance
7. Long term propranolol treatment and changes in body weight after myocardial infarction
8. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults
9. Overweight is risking fate: Definition, classification, prevalence, and risks
10. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial
11. Effect of antihypertensive therapy on weight loss: The Trial of Antihypertensive Interventions and Management Research Group
12. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension
13. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients
14. Influence of beta-adrenergic blockade on glucose-induced thermogenesis in man
15. A 24-h energy expenditure study on reduced-obese and nonobese women: Effect of beta-blockade
16. Long-term antihypertensive therapy with beta-blockers: Submaximal exercise capacity and metabolic effects during exercise
17. Thermic effect of glucose in man: Obligatory and facultative thermogenesis
18. Role of the autonomic nervous system in the thermogenic response to food in lean individuals
19. Reduced metabolic rate during beta-adrenergic blockade in humans
20. Resting metabolic rate and substrate use in obesity hypertension
21. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle
22. Stimulation of thermogenesis by carbohydrate overfeeding
23. Effect of clonidine on the thermic effect of feeding in humans
24. The thermic effect of food and obesity: A critical review
25. Role of nonexercise activity thermogenesis in resistance to fat cain in humans
26. Beta-adrenoceptor blockade and exercise: An update
27. Regulation of body weight
28. Clinical pharmacology of beta 3-adrenoceptors
29. Effects of short-term and long-term treatment with cardio-selective and non-selective beta-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise
30. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene
31. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity
32. Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients
33. The different effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females
34. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity
35. The thermic effect of feeding in older men: The importance of the sympathetic nervous system
36. Impairment of health and quality of lite in people with large waist circumference
37. Is visceral adiposity a significant correlate of subcutaneous adipose cell lipolysis in men?
38. Guidelines Subcommittee
39. Hypertension in diabetes study III. Prospective study of therapy of hypertension in type 2 diabetic patients: Efficacy of ACE inhibition beta-blockade
40. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
41. Correction of remodeling and function of small arteries in human hypertension by cilazapril an angiotensin I-converting enzyme inhibitor
42. The effect of captopril and metoprolol as monotherapy or combined with bendroflumethiazide on blood lipids
43. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies: The Treatment of Mild Hypertension Research Group
44. Effect of angiotension-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
45. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigations
46. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study
47. Primary prevention with metoprolol in patients with hypertension: Mortality results from the MAPHY study
48. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic: A 10-year controlled trial with bendroflumethiazide